Prostate Cancer - 2/17

Entry	Author	Date	Location
The Resurgence of Gene and Cell Therapy	Barrie Carter	05/16/11	Seattle
Varian Invests $15M in Augmenix	Luke Timmerman	05/12/11	Boston
Dendreon Gets $28M Revenue in Q1	Luke Timmerman	05/02/11	Seattle
J&J Wins Early Approval of Potential Prostate Cancer Blockbuster	Arlene Weintraub	04/29/11	New York
San Diego’s Polaris Moves to Late-Stage Test of Drug for Liver Cancer and Other “Arginine-Dependant” Tumors	Bruce V. Bigelow	04/27/11	San Diego
Medivation Flunks Huntington’s Trial, Calibra Nabs Venture Cash, Open Source Biology Comes to SF, & More Bay Area Life Sciences News	Luke Timmerman	04/15/11	San Francisco
T2 Biosystems, On-Q-ity, and GnuBIO Report Progress in Hunting for Signs of Disease	Ryan McBride	04/07/11	Boston
Dendreon Wins Full Reimbursement From Medicare for $93K Prostate Cancer Drug	Luke Timmerman	03/30/11	Seattle
Tekmira Sues Alnylam, Alan Aderem Bolts to Seattle BioMed, Dendreon’s Warhorse Retires, & More Seattle-Area Life Sciences News	Luke Timmerman	03/17/11	Seattle
Dendreon’s Warhorse, Chief Scientific Officer Dave Urdal, To Retire at Year-End	Luke Timmerman	03/11/11	Seattle
Exelixis Pockets $156M in Stock Sale, Riding Wave of Prostate Cancer Drug Results	Luke Timmerman	03/09/11	San Francisco
Calypso Medical’s New CEO Seeks to Steady Ship After a Rough Couple of Years	Luke Timmerman	03/09/11	Seattle
Dendreon Makes It Official, Grabs Downtown Office and Former Zymo Lab Building	Luke Timmerman	03/01/11	Seattle
Metamark, Stealthy Startup with Dana-Farber Roots, Seeks to Tell Docs When to Treat Prostate Cancer, and When Not	Ryan McBride	02/24/11	Boston
Dendreon Scopes Out Downtown Seattle Headquarters	Luke Timmerman	02/18/11	Seattle
Genomic Health, Taking a Hit on Bottom Line, Bets Next-Gen Sequencing Will Yield Next-Gen Diagnostics	Luke Timmerman	02/15/11	San Francisco
Calypso Pulls in $6.4M	Luke Timmerman	01/21/11	Seattle
Dendreon Plans to Go It Alone in Europe, Build Provenge Factory in Germany	Luke Timmerman	01/07/11	Seattle
Vaccines Top the List of 2010 Innovations	Larry Corey	12/27/10	Seattle
Editor’s Picks: The Best of 2010 From Xconomy Seattle	Luke Timmerman	12/23/10	Seattle
Roche Cutting Hundreds of Jobs, Exelixis Shares Soar, Sutro Pockets $36.5M, & More Bay Area Life Sciences News	Luke Timmerman	11/19/10	San Francisco
Dendreon Survives Medicare Panel, Arch’s Ouch, RNAi Shock Wave Hits Tekmira, & More Seattle-Area Life Sciences News	Luke Timmerman	11/18/10	Seattle
Dendreon Passes Medicare Panel’s Questions About Provenge Effectiveness	Luke Timmerman	11/17/10	Seattle
Dendreon Prepares to Take Some Heat in the Other Washington Over Cancer Drug Prices	Luke Timmerman	11/16/10	Seattle
Genomic Health Seeks to Build Momentum For Healthcare Shift from Rx to Dx	Luke Timmerman	11/08/10	San Francisco
Dendreon’s Plan to Meet Demand, Arch Banks on Ikaria IPO, RF Surgical Leaves No Sponge Behind, & More Seattle-Area Life Sciences News	Luke Timmerman	11/04/10	Seattle
Dendreon, Hemmed in By Tight Supply, Sees $350M to $400M in 2011 Sales Plan	Luke Timmerman	11/03/10	Seattle
Dendreon’s Provenge Launch Story Enters Second Chapter, With Today’s Earnings Call	Luke Timmerman	11/03/10	Seattle
Compendia Bioscience Morphs Into Big Pharma’s Cancer Genomics Partner	Ryan McBride	10/21/10	Detroit
FDA Panel Votes Against Arena’s Weight-Loss Drug, ImThera Encouraged by Early Test Results, Novartis Wins FDA Approval for MS Pill, & More San Diego Life Sciences News	Bruce V. Bigelow	09/23/10	San Diego
Page 2 of 6	« previous page · next page »

Entry

Author

Date

Location

The Resurgence of Gene and Cell Therapy

Barrie Carter

05/16/11

Seattle

Varian Invests $15M in Augmenix

Luke Timmerman

05/12/11

Boston